Park Ha Biological Technology Co., Ltd. (BYAH) AI Stock Summary

Snapshot

Park Ha Biological is a tiny skincare company in financial distress. The business generated only $2.5M in revenue last year, but reported a staggering $24.4M net loss. This loss is driven by a $24.1M operating loss, which is nearly ten times the company's total revenue. While the company holds $3.8M in cash against negligible debt, the core operations are burning through capital at an unsustainable rate. The stock underwent a 1-for-50 reverse split in February 2026, a move that typically signals a stock has been under severe pressure for a long time. The share count also increased by 12.4% year-over-year, diluting existing shareholders further.

What's Happening Right Now

• Fri 5th Jun '26 · Compliance: The company filed a Form 6-K to disclose its election to rely on home country practice exemptions, opting out of several Nasdaq corporate governance requirements like having a majority independent board.
• Mon 13th Apr '26 · Lawsuit: Rosen Law Firm announced an investigation into potential securities claims, alleging the company issued misleading business information to investors.

Ownership

Institutions hold 0.1% of the company, while insiders hold 0.0%.

Bottom Line

This is a classic micro-cap distress signal. The company is losing more than ten times its revenue in operating costs, which is not a temporary setback but a fundamental failure of the business model. The recent reverse split and the pending securities investigation add serious risk. While the cash balance provides a long runway on paper, the operational bleeding is severe. A reader should view this as a highly speculative name with significant red flags.